Ionis Pharmaceuticals Announces FDA Approval of ZANVASTRO for Alexander Disease

What Happened
Ionis Pharmaceuticals filed a Form 8-K (filed 2026-09-04) announcing that on September 3, 2026 the U.S. Food and Drug Administration approved ZANVASTRO™ (zilganersen) for the treatment of Alexander disease (AxD) in pediatric and adult patients. Ionis describes ZANVASTRO as the first and only disease‑modifying treatment for AxD; the approved dose is 50 mg administered quarterly by intrathecal injection. The approval was supported by positive pivotal study results, and Ionis said the drug will be available in the U.S. in the coming weeks.

Key Details

• FDA approval announced Sept 3, 2026; Form 8-K filed Sept 4, 2026 (Regulation FD disclosure and Other Events).
• Dose/administration: ZANVASTRO 50 mg, given quarterly via intrathecal injection.
• Pivotal study: in patients ≥5 years, ZANVASTRO showed statistically significant stabilization of gait speed (10‑Meter Walk Test) at Week 61 — least square mean difference 33.3%, p = 0.041; patients 2–4 years showed improvement on GMFM‑88 at Week 61.
• Additional items: favorable safety/tolerability reported; FDA granted Ionis a Priority Review Voucher. In June 2026 Ionis licensed ex‑U.S. rights to Recordati, which will pursue regulatory submissions in Europe and Japan expected in 2027.

Why It Matters
This is a material development for Ionis because ZANVASTRO is the company’s newly approved, first‑in‑class disease‑modifying therapy for a rare, progressive neurological disorder. Approval enables near‑term U.S. commercialization and may generate regulatory milestones and/or royalties under the Recordati license for ex‑U.S. markets. The Priority Review Voucher may help accelerate future filings. The filing also includes standard forward‑looking statement disclaimers and refers investors to Ionis’ public SEC filings (Form 10‑K and Form 10‑Q) for risk details.